(3E)-3-benzylidene-1-methyl-N-[(4-methylsulfanylphenyl)methyl]-2-oxo-4H-quinoline-6-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (3E)-3-benzylidene-1-methyl-N-[(4-methylsulfanylphenyl)methyl]-2-oxo-4H-quinoline-6-carboxamide
• 化学式: C₂₆H₂₄N₂O₂S
• 分子量: 428.5
• InChiKey: CRKALXDCRGBCBZ-HYARGMPZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  74.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• 3,4-Dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20040043984A1

  公开（公告）日：2004-03-04

  This invention provides compounds defined by Formula I 1 or a pharmaceutically acceptable salt thereof, wherein R 1 , Q, Y 1 , Y 5 , Y 6 , Y 8 , R 2 , R 2a , and R 4 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.
• [EN] 3,4-DIHYDROQUINOLIN-2-ONE, 5,6-FUSED OXAZIN-3-ONE, AND 5,6-FUSED THIAZIN-3-ONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] INHIBITEURS DE METALLOPROTEASES MATRICES A BASE DE DERIVES DE 3,4-DIHYDROQUINOLINE-2-ONE, D'OXAZINE-3-ONE FUSIONNEE EN 5,6, ET DE THIAZINE-3-ONE FUSIONNEE EN 5,6
  申请人：WARNER LAMBERT CO

  公开号：WO2004014389A1

  公开（公告）日：2004-02-19

  This invention provides compounds'defined by Formula I or a pharmaceutically acceptable salt thereof,wherein Rt, Q, Y1, Y5, Y6, Y8, R2, R2a, and R4 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I and the use of the compounds of Formula .1 as matrix metalloproteinase inhibitors.